How Much Does Jardiance Cost in 2026?
Jardiance (empagliflozin) is a once-daily tablet used for type 2 diabetes, heart failure and chronic kidney disease. Medicare's negotiated price took effect on January 1, 2026: $197 for a 30-day supply, 66% below the $573 list price. There is no generic empagliflozin and there will not be one until about 2029, but the closest drug in its class, Farxiga, now has a generic, which creates a conversation worth having with your prescriber.
- Medicare's negotiated price is $197 per 30-day supply, in effect since January 1, 2026, down from a $573 list price.
- No generic empagliflozin exists in the United States and none is expected until roughly 2029 or later.
- The same-class alternative dapagliflozin (generic Farxiga) became available in 2026 and is currently the only generic SGLT2 inhibitor in the US.
- Jardiance and Farxiga have overlapping but not identical approved uses, so whether a switch is appropriate is a clinical question for your prescriber, not a price question.
What You Actually Pay
Figures are for a 30-day supply. List and negotiated prices are from CMS; what you pay depends on your coverage.
| Your situation | Typical cost |
|---|---|
| Medicare negotiated price, 2026 | $197 / 30 days |
| Medicare Part D, your share | up to $2,100 / year |
| Commercial insurance | copay or coinsurance |
| Uninsured, cash | ~$573 (list) |
The Only Generic in This Class Is Not This Drug
Jardiance belongs to a class called SGLT2 inhibitors. Until recently none of them had a generic in the US. That changed in 2026 when the FDA approved the first true generic dapagliflozin, the active ingredient in Farxiga. It is the only generic SGLT2 inhibitor available here, and generic entry normally pushes a price well below any negotiated figure.
That makes a genuine question available to you that was not available a year ago: is dapagliflozin a reasonable option for your situation? Sometimes yes, sometimes no. The two drugs have overlapping but different approved indications and different trial evidence behind each use, and your kidney function and your specific diagnosis matter. This is a question to put to your prescriber with the price information in hand, not a substitution to request at the pharmacy counter. An SGLT2 inhibitor is not interchangeable the way two versions of the same molecule are.
What Medicare's Negotiated Price Does, and Does Not, Change
The headline number is not your copay.
$197 is the maximum fair price, the amount Medicare and your Part D plan pay for a 30-day supply of Jardiance. What you are charged at the counter is still set by your plan's tier and cost-sharing rules.
It helps you directly if you pay coinsurance
Many plans charge a percentage of the drug's price on brand and specialty tiers. If you owe 25% of $573, that is far more than 25% of $197. When your share is a percentage, a lower negotiated price lowers your bill directly.
It may not change a flat copay
If your plan charges a fixed dollar copay for that tier, your copay can stay the same even though the plan is paying less. The benefit then shows up in the program's overall costs rather than your receipt.
It changes how fast you hit the cap
Your spending counts toward the $2,100 annual Part D out-of-pocket cap in 2026. A cheaper drug means a smaller share each month, which can mean you reach the cap later or not at all, so the year-end picture differs from past years.
It does not change coverage rules
A negotiated price does not force a plan to cover Jardiance, drop prior authorization, or change its tier. Plans still set their own formularies, so check yours before you assume the new price applies to you.
Because tiers and cost-sharing vary so much between plans, the only way to know your real cost is to check Jardiance against each plan's formulary. If you would rather have that done for you, our Find My Medicare Plan service checks your specific drugs against the plans available to you for a flat $99.
Is There a Generic for Jardiance?
No. There is no FDA-approved generic empagliflozin in the United States, and patents are expected to keep one off the market until roughly 2029 or later. The notable alternative is that generic dapagliflozin, the active ingredient in Farxiga, became available in 2026 and is the only generic in this drug class. Whether it suits you is a clinical decision for your prescriber.
Does Insurance Cover Jardiance?
Usually, with conditions
Jardiance is covered by Medicare Part D and most commercial plans, typically on a preferred or non-preferred brand tier, often with prior authorization and sometimes step therapy. Coverage can also depend on which indication you are being treated for, since the drug is approved for diabetes, heart failure and chronic kidney disease and some plans apply different rules to each.
If you are denied or moved a tier
A denial is not the end, and a tier change at renewal is not either. Your prescriber can submit a letter of medical necessity or a formulary exception, and you have formal appeal rights. See how to appeal an insurance denial and what to do when a plan drops your drug.
How to Pay Less
Ask whether generic dapagliflozin is an option for you
It is the only generic SGLT2 inhibitor in the US. It is not an automatic substitute and the indications are not identical, so this is a prescriber conversation. If the answer is yes, it is likely the cheapest route in this class.
On commercial insurance, check the manufacturer savings card
Boehringer Ingelheim and Lilly run a savings program that can reduce a commercial copay significantly. It cannot be used with Medicare, Medicaid or other federal coverage.
On Medicare, check Extra Help and the payment plan
Extra Help (the Low Income Subsidy) sharply reduces Part D costs and its income limits are higher than most people expect. The Medicare Prescription Payment Plan can also spread your Part D costs evenly across the year instead of front-loading them, and you opt in through your plan.
Check the tier before you commit to a plan
The same drug can cost very different amounts across plans in the same ZIP code. During open enrollment, compare Jardiance on each plan's formulary, and remember the plan that was cheapest last year may not be this year.
Push back on a bill you have already received
If you were billed more than you expected, or a claim was processed wrong, CareRoute Bill Defense reviews and disputes medical bills, with no fee unless we save you money.
Not sure which plan covers Jardiance best?
For a flat $99, we research the Medicare plans available to you and check them against your specific drugs and doctors, then hand you a clear comparison. We are independent, sell no insurance, and take no commissions.
Frequently Asked Questions
Is there a generic for Jardiance?
No. There is no FDA-approved generic empagliflozin in the United States, and patent protection is expected to keep one off the market until about 2029 or later. The closest development is that generic dapagliflozin, the active ingredient in Farxiga, became available in 2026 and is currently the only generic SGLT2 inhibitor sold here. Whether switching is appropriate depends on your diagnosis, your kidney function and the evidence for each drug in your specific condition, so it is a question for your prescriber.
Is Jardiance or Farxiga cheaper on Medicare?
Both were in the first round of Medicare negotiation, with prices effective January 1, 2026: Farxiga at $178 for a 30-day supply and Jardiance at $197, so Farxiga is slightly lower at the Medicare level. The bigger difference is that generic dapagliflozin became available in 2026 while generic empagliflozin is years away, so Farxiga has a cheaper route that Jardiance does not. Your own copay still depends on your plan's tier for each drug. They are not interchangeable, though, and the clinical choice belongs with your prescriber.
What is Medicare's negotiated price for Jardiance?
Medicare negotiated a maximum fair price of $197 for a 30-day supply of Jardiance, effective January 1, 2026. That is 66% below the $573 list price CMS used as the comparison. Jardiance was one of the first ten drugs in the Medicare Drug Price Negotiation Program, selected because it was among the highest-spending Part D drugs without generic or biosimilar competition at the time. The price applies automatically at the pharmacy for Part D members.
Will the negotiated price lower what I actually pay for Jardiance?
It can, but it is not your new copay. The maximum fair price is what Medicare and your Part D plan pay the pharmacy, not automatically what you are charged. If your plan charges coinsurance, a percentage of the drug price, a lower negotiated price lowers your share directly. If your plan charges a flat copay for that tier, your copay may not change at all. Either way, your total Part D out-of-pocket is capped at $2,100 in 2026, after which covered drugs cost you nothing for the rest of the year.
Does insurance cover Jardiance?
Generally yes. Jardiance is covered by Medicare Part D and most commercial plans, though plans commonly require prior authorization and sometimes step therapy, meaning you try a cheaper option first. The tier it sits on, not whether it is covered, is usually what decides your cost, and the same drug can sit on different tiers in two plans sold in the same ZIP code. Check your plan's formulary for the tier and any restrictions before you fill it.
Related
Sources
- CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (maximum fair price and list-price comparison)
- CMS / Medicare.gov (Part D out-of-pocket cap, $2,100 in 2026, and the $615 maximum deductible)
- FDA Orange Book and Purple Book (approval and substitutability status for empagliflozin)
- Boehringer Ingelheim and Eli Lilly published list price and patient-support program terms
Prices are national figures for a 30-day supply at a common dose and vary by pharmacy, dose, and plan. List prices are the figures CMS published as its negotiation comparison. This page is educational and is not medical or financial advice: do not start, stop, or switch a prescription on the basis of price without talking to your prescriber. Last updated November 20, 2026.